Effect of intercalated erlotinib with gemcitabine/cisplatin as neoadjuvant treatment in stage IIIA unrectable non-small cell lung cancer (CTONG 1101, NCT01297101) on disease-free survival: A single arm, multi-center, phase II study.

被引：0
|
作者：
Chen Zhiwei
Jiang Gening
Xin, Wang
Luo, Qingquan
Lu, Shun
机构：
[1] Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Canc Ctr, Shanghai 200030, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Surg Oncol, Shanghai 200092, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Dept Surg Oncol, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200030, Peoples R China
[5] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18519
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II single-arm trial comparing the use of FLT PET/CT to standard computed tomography to assess the treatment response of neoadjuvant docetaxel and cisplatin in stage IB-IIIA resectable non-small cell lung cancer
    Crandall, John
    Shankar, Lalitha
    Wahl, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [32] Neoadjuvant chemotherapy with bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer: Survival results from a phase II feasibility study (NAVAL)
    Tsutani, Y.
    Miyata, Y.
    Suzuki, K.
    Takamochi, K.
    Tanaka, F.
    Nakayama, H.
    Yamashita, Y.
    Oda, M.
    Tsuboi, M.
    Okada, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Camrelizumab plus platinum doublet chemotherapy as adjuvant treatment of stage IIA-IIIA non-small cell lung cancer: A phase II, single-arm research
    Xu, H.
    Kong, X.
    Zhao, S.
    Zhu, K.
    Shi, B.
    Wang, Y.
    Ni, B.
    Han, B.
    Hou, J.
    Bu, J.
    Gu, Y.
    Ren, F.
    Xu, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1621 - S1621
  • [34] Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China
    Helei Hou
    Yongjie Wang
    Dantong Sun
    Jingjuan Zhu
    Man Jiang
    Xuchen Zhang
    Na Zhou
    Chuantao Zhang
    Tianjun Li
    Xiaochun Zhang
    Investigational New Drugs, 2023, 41 : 86 - 92
  • [35] Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China
    Hou, Helei
    Wang, Yongjie
    Sun, Dantong
    Zhu, Jingjuan
    Jiang, Man
    Zhang, Xuchen
    Zhou, Na
    Zhang, Chuantao
    Li, Tianjun
    Zhang, Xiaochun
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 86 - 92
  • [36] A National, Multi Center, Randomized, Open-label, Phase II Study of Erlotinib Versus Gemcitabine (GEM) Plus Cisplatin as Neoadjuvant Treatment in Stage IIIA-N2 Non-small-cell Lung Cancer (NSCLC) Patients (pts) With Activating EGFR Mutations (C-TONG 1103)
    Zhong, W.
    Wu, Y.
    Wang, C.
    Mao, W.
    Xu, L.
    Cheng, Y.
    Yang, X.
    Chen, K.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S602 - S603
  • [37] Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study
    Blakely, Collin M.
    Urisman, Anatoly
    Gubens, Matthew A.
    Mulvey, Claire K.
    Allen, Greg M.
    Shiboski, Stephen C.
    Rotow, Julia K.
    Chakrabarti, Turja
    Kerr, D. Lucas
    Aredo, Jacqueline V.
    Bacaltos, Bianca
    Gee, Megan
    Tan, Lisa
    Jones, Kirk D.
    Devine, W. Patrick
    Doebele, Robert C.
    Aisner, Dara L.
    Patil, Tejas
    Schenk, Erin L.
    Bivona, Trever G.
    Riess, Jonathan W.
    Coleman, Melissa
    Kratz, Johannes R.
    Jablons, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (26)
  • [38] Pilot phase II study of neoadjuvant docetaxel (T) and cisplatin (P) followed by adjuvant erlotinib (E) in patients with stage I-III non-small cell lung cancer (NSCLC)
    Gold, Kathryn A.
    Lee, J. Jack
    Rice, David
    Tse, Warner
    Stewart, David
    Wistuba, Ignacio I.
    Herbst, Roy S.
    Lippman, Scott M.
    Hong, Waun K.
    Kim, Edward S.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S784 - S785
  • [39] ERLOTINIB AS NEOADJUVANT TREATMENT IN ENDOBRONCHIAL ULTRASOUND CONFIRMED STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION (EXON 19 OR 21) (NCT01217619, ESTERN): A PROSPECTIVE, SINGLE ARM, PHASE II CLINICAL TRIAL
    Han, B.
    Xiong, L.
    Sun, J.
    Li, R.
    Lou, Y.
    Zhang, Y.
    Gu, A.
    Jiang, L.
    Shi, J.
    ANNALS OF ONCOLOGY, 2015, 26
  • [40] ERLOTINIB AS NEOADJUVANT TREATMENT IN PATIENTS WITH STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER (NSCLC) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION (NCT01217619, EASTERN): STUDY UPDATE
    Han, Baohui
    Xiong, Liwen
    Sun, Jiayuan
    Li, Rong
    Lou, Yuqing
    Zhang, Yanwei
    Gu, Aiqing
    Jiang, Liyan
    Shi, Jianxin
    Fang, Wentao
    Zhao, Heng
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S917 - S918
12345